跳至主要内容
临床试验/NCT01322412
NCT01322412已完成不适用

Adapted Physical Activity Effect on Aerobic Function and Fatigue in Patients With Breast Cancer Treated in Adjuvant Phase

University Hospital, Limoges1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2011年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
44
试验地点
1
主要终点
main criterion is exercise tolerance at 27 weeks, measured by VO2 max, following a physical activity (PA) programme

研究概览

简要总结

Physical exercise has been identified as a major item of many chronic diseases and cancer rehabilitation.

Therefore, physical activity for health is a valid and relevant way to improve quality of life and to manage cancer patient fatigue. The aim of the study is the assessment of the effects of a physical activity retraining program on aerobic capacity, strength and fatigue, in a breast cancer population treated by adjuvant chemotherapy.

详细描述

Physical exercise has been identified as a major item of many chronic diseases and cancer rehabilitation. It contributes to an improvement in the quality of life and to a decrease in the current treatment side effects and mortality. Cancer in association with treatment toxicity and an inactive lifestyle lead to a fall in physical capability and causes problems in daily activities. The physical capacity and the tolerance for exercise fall simultaneously leading to a deconditioning vicious circle which increases physical, psychological and emotional symptoms of fatigue. Therefore, physical activity for health is a valid and relevant way to improve quality of life and to manage cancer patient fatigue. The aim of the study is the assessment of the effects of a physical activity retraining program on aerobic capacity, strength and fatigue, in a breast cancer population treated by adjuvant chemotherapy.

A total of 44 subjects is required. The programme is organised as follows: Arm A (aerobic and strength training) and during the 27 weeks of treatment (chemotherapy and radiotherapy); Arm B (control group). This study includes 3 assessments phases (T0: before adjuvant chemotherapy; T1 (week 27) and T2: final evaluation at the 54th week). These assessments include: cardiopulmonary exercise test including maximal oxygen uptake test (VO2max), six-minute walk test, muscular testing, assessment of physical activity (IPAQ questionnaire), fatigue (MFI20 questionnaire), quality of life (EORTC QLQ C30), anxiety and depression symptoms (HADS) and nutritional evaluation: BMI and total body photonic absorption.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • females between 18 and 75 years of age
  • signed written informed consent
  • willing to take part in the trial and to follow the instructions
  • breast tumour, histologically documented
  • patients who have undergone curative surgery
  • patients for whom a 6-treatment course of adjuvant chemotherapy (3FEC100 + taxanes) and radiotherapy has been scheduled
  • patients with HER2-negative cancer.

排除标准

  • metastatic cancer
  • other primary tumours
  • disability preventing a proper understanding of the instructions for the trial
  • chemotherapy strictly contra-indicated
  • patients who are subject to a court protection, wardship or guardianship order
  • uncontrolled hypertension
  • family history of sudden death in a first-degree relative
  • unstabilised heart disease
  • current treatment with beta-blockers
  • chronic or acute pulmonary disease associated with dyspnoea upon moderate effort
  • uncontrolled thyroid dysfunction
  • uncontrolled diabetes
  • any other serious conditions that are unstabilised, disabling or in which physical exercise is contra-indicated
  • unable to attend for follow-up throughout the duration of the study
  • ventricular ejection fraction (vef) < 50%, pregnancy or suckling.

结局指标

主要结局

main criterion is exercise tolerance at 27 weeks, measured by VO2 max, following a physical activity (PA) programme

时间窗: 27 weeks

次要结局

  • Assessment at 27 and 54 weeks between the 2 groups of muscle function.(54 weeks)

研究者

发起方
University Hospital, Limoges
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验